Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Applied Spectral Imaging Launches Two New Products for the Digital Pathology Market

Applied Spectral Imaging (ASI)
Posted on: 04 Oct 17
Applied Spectral Imaging Launches Two New Products for the Digital Pathology Market State of the Art Systems for Brightfield and FISH Imaging & Analysis

PR Newswire

CARLSBAD, California, Oct. 4, 2017

CARLSBAD, California, Oct. 4, 2017 /PRNewswire/ -- Applied Spectral Imaging (ASI), a global leader in computer-assisted biomedical imaging, announced today the launch of PathFusion™ and HiPath Pro™, innovative Brightfield and FISH imaging & analysis solutions for pathology. ASI will unveil the new products at the upcoming CAP2017 meeting in Maryland, October 8-10, 2017.

The PathFusion system is a cutting-edge workflow solution, bridging the gap between Brightfield pathology and FISH. Combining microscope-based Whole Slide Imaging, industry-leading Tissue FISH applications and revolutionary digital tissue matching of FISH with H&E/IHC samples, it provides accurate and validated analysis for higher diagnostic confidence. Powered by GenASIs, PathFusion supports a wide range of sample types, IHC antibodies and FISH probes, and features modern digital workflows that increase laboratory productivity and improve FTE savings.

HiPath Pro is a unique Brightfield imaging & analysis system for a variety of histopathology needs, including Whole Slide Imaging of H&E/IHC samples and Quantitative IHC Scoring of membrane and nuclear stains. Through exceptional image quality and precise computer-assisted analysis, it provides uncompromising results standardization, in addition to streamlining communication and simplifying sharing processes. The HiPath Pro manual configuration is FDA cleared for IHC Family HER2/neu, ER, PR and Ki-67.

"We are excited to introduce these new breakthrough technologies, demonstrating once again our relentless commitment to advancing patient diagnostics", said Limor Shiposh, CEO of ASI. "PathFusion and HiPath Pro, both powered by our proprietary GenASIs algorithms, address the most pressing needs of modern pathology laboratories: digital workflows that increase productivity, labor efficiencies, data accessibility and above all, standardized results through accurate, consistent analysis."

Visit the ASI booth #805 at the CAP2017 meeting to learn more.

About ASI
ASI is a global leader in the development of biomedical imaging solutions, supporting fluorescent, Brightfield and spectral image-acquisition, for the Pathology and Cytogenetics markets.

HiPath Pro™ and PathFusion™, powered by GenASIs™, are automated imaging platforms that provide advanced diagnostic aids for pathologists, with reproducible and standardized results. ASI platforms support manual and automatic scanning for a wide range of workflows and applications, to best suit the needs, size and budget of any laboratory. 

ASI's applications are FDA cleared for BandView, FISHView, CEP XY, UroVysion, ALK, HER2/neu FISH and IHC Family for: HER2, ER, PR and Ki67.

ASI serves clinical laboratories, life science companies and research institutions in over 50 countries.

www.appliedspectralimaging.com/digitalpathology

For More Information Please Contact 
Applied Spectral Imaging 
Phone: +1 (760) 929-2840
E-mail: info@spectral-imaging.com

 

View original content with multimedia:http://www.prnewswire.com/news-releases/applied-spectral-imaging-launches-two-new-products-for-the-digital-pathology-market-300530430.html

SOURCE Applied Spectral Imaging (ASI)

PR Newswire
www.prnewswire.com

Last updated on: 04/10/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.